Murali Arvind R, Kotwal Vikram, Chawla Saurabh
Arvind R Murali, Department of Gastroenterology and Hepatology, University of Iowa Hospitals and Clinics, Iowa City, IA 52246, United States.
World J Hepatol. 2015 Sep 8;7(19):2194-201. doi: 10.4254/wjh.v7.i19.2194.
Hepatitis E viral infection has traditionally been considered an acute, self-limited, water borne disease similar to hepatitis A, endemic to developing countries. However, over the past decade, zoonotic transmission and progression to chronicity in human patients has been identified, resulting in persistently elevated transaminase levels, progressive liver injury and cirrhosis. In addition to liver injury, neurological, renal and rheumatological manifestations have also been reported. Chronic hepatitis E occurs mainly in immunosuppressed individuals such as transplant recipients, human immunodeficiency virus patients with low CD4 counts and in patients with hematological malignancies receiving chemotherapy. Diagnosis is established by persistent elevation of hepatitis E virus RNA in the stool or serum. This population often requires treatment with antiviral agents, particularly ribavirin, as spontaneous clearance with reduction in immunosuppression occurs only in about a third of the patients. The purpose of this review, is to further discuss the clinical presentation, and recent advances in diagnosis, treatment and prophylaxis of chronic hepatitis E.
戊型肝炎病毒感染传统上被认为是一种急性、自限性、经水传播的疾病,类似于甲型肝炎,在发展中国家呈地方性流行。然而,在过去十年中,已发现戊型肝炎存在人畜共患传播以及在人类患者中发展为慢性的情况,导致转氨酶水平持续升高、进行性肝损伤和肝硬化。除肝损伤外,还报告了神经、肾脏和风湿方面的表现。慢性戊型肝炎主要发生在免疫抑制个体中,如移植受者、CD4计数低的人类免疫缺陷病毒患者以及接受化疗的血液系统恶性肿瘤患者。通过粪便或血清中戊型肝炎病毒RNA持续升高来确诊。这类人群通常需要使用抗病毒药物进行治疗,尤其是利巴韦林,因为只有约三分之一的患者在免疫抑制减轻后能自发清除病毒。本综述的目的是进一步讨论慢性戊型肝炎的临床表现以及诊断、治疗和预防方面的最新进展。